U.S. Markets closed
  • S&P Futures

    3,879.75
    +12.25 (+0.32%)
     
  • Dow Futures

    31,443.00
    +85.00 (+0.27%)
     
  • Nasdaq Futures

    13,117.00
    +61.75 (+0.47%)
     
  • Russell 2000 Futures

    2,243.00
    +13.90 (+0.62%)
     
  • Crude Oil

    59.40
    -0.35 (-0.59%)
     
  • Gold

    1,733.10
    -0.50 (-0.03%)
     
  • Silver

    26.82
    -0.06 (-0.24%)
     
  • EUR/USD

    1.2090
    +0.0003 (+0.0242%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • Vix

    24.10
    +0.75 (+3.21%)
     
  • GBP/USD

    1.3959
    +0.0003 (+0.0209%)
     
  • USD/JPY

    106.7600
    +0.0500 (+0.0469%)
     
  • BTC-USD

    48,618.53
    -980.26 (-1.98%)
     
  • CMC Crypto 200

    972.39
    -14.26 (-1.45%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,394.91
    -13.26 (-0.05%)
     

A Look Into Healthcare Sector Value Stocks

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

What Defines a Value Stock?

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Below is a list of notable value stocks in the healthcare sector:

  1. AIkido Pharma (NASDAQ:AIKI) - P/E: 3.26

  2. Bio-Rad Laboratories (NYSE:BIO) - P/E: 5.19

  3. Coherus BioSciences (NASDAQ:CHRS) - P/E: 8.47

  4. Exagen (NASDAQ:XGN) - P/E: 0.31

  5. OpGen (NASDAQ:OPGN) - P/E: 0.4

AIkido Pharma has reported Q3 earnings per share at -0.06, which has increased by 14.29% compared to Q2, which was -0.07. AIkido Pharma does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Bio-Rad Laboratories saw an increase in earnings per share from 1.61 in Q2 to 3.0 now. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Coherus BioSciences has reported Q3 earnings per share at 0.47, which has decreased by 41.98% compared to Q2, which was 0.81. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Exagen's earnings per share for Q3 sits at -0.34, whereas in Q2, they were at -0.27. Exagen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

OpGen saw an increase in earnings per share from -0.49 in Q2 to -0.4 now. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.